Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$29.88 USD
+0.17 (0.57%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $29.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
HRMY 29.88 +0.17(0.57%)
Will HRMY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for HRMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HRMY
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
HRMY or TECH: Which Is the Better Value Stock Right Now?
HRMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
HRMY vs. TECH: Which Stock Is the Better Value Option?
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
HRMY or ILMN: Which Is the Better Value Stock Right Now?
Other News for HRMY
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1
Harmony releases promising phase 2 results of pitolisant for myotonic dystrophy
Harmony presents data from Phase 2 signal detection study of pitolisant
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo